Active — Presolicitation / Notice of Intent to Sole Source
NOI-OD-26-009308
NIH 10X Genomics Reagents for Early Detection of Lung Diseases — NOI-OD-26-009308
FundingNo fixed maximum contract value verified from the controlling official source.
DeadlineSeptember 23, 2026 at 11:00 AM EST, as stated in the federal notice
Last verifiedSeptember 19, 2026
Required next actionTreat this as a notice of intent, not an RFQ. Review the live SAM.gov notice and posted justification before submitting any comment. Proceed only if a legitimate proprietary-supply or technically equivalent basis can be documented. Targeted WorkDrive review found no documented Dr. Miltie 10X Genomics/Chromium reagent capability, so no direct pursuit is being opened.
Broad Eligibility
NIH intends a sole-source award to 10X Genomics for proprietary Chromium-compatible reagents. Other parties should not be treated as viable sources unless they can authoritatively demonstrate a compliant alternative under the controlling notice.
Atlas Analysis
NIH intends a one-year sole-source award to 10X Genomics for proprietary Chromium-compatible GEM-X reagents supporting early lung-disease biomarker research. The notice states that no solicitation will be issued and quotations are not requested; comments may be submitted by September 23, 2026 at 11:00 AM EST. Targeted WorkDrive review found no documented Dr. Miltie manufacturer/reseller or equivalent proprietary reagent capability.
Opportunity Overview
NIH has issued NOI-OD-26-009308, a notice of intent to award a one-year firm-fixed-price sole-source contract to 10X Genomics for proprietary reagents and consumables supporting the Early Detection of Lung Diseases project.
Current Federal Status
This is a presolicitation notice, not a request for quotation. NIH states that no solicitation document will be issued and quotations will not be requested. Comments referencing the posting may be submitted by September 23, 2026 at 11:00 AM EST, as stated in the federal notice.
Technical Basis
The requirement covers GEM-X Universal 5′ Gene Expression v3 reagents and consumables specifically designed for the 10X Genomics Chromium platform. NIH states that the proprietary compatibility is necessary for continuity, reproducibility, and integrity of single-cell and multiomic lung-disease research, and that alternative supplies cannot meet the technical requirement.
Direct-Vendor Assessment
A targeted Dr. Miltie WorkDrive review found no documented 10X Genomics manufacturer/reseller authorization or equivalent proprietary reagent capability. Atlas is not opening a speculative direct-vendor challenge.
Official Source
View the official SAM.gov notice
Source verificationOfficial government source · sam.govAtlas last verified this record September 19, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
